132 related articles for article (PubMed ID: 38653155)
21. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
22. Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients.
Hanania HL; Lewis DJ
J Dermatolog Treat; 2022 Dec; 33(8):3119-3126. PubMed ID: 36018250
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
Kaufman HL; Schwartz LH; William WN; Sznol M; Fahrbach K; Xu Y; Masson E; Vergara-Silva A
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2245-2261. PubMed ID: 30132118
[TBL] [Abstract][Full Text] [Related]
24. Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy.
Lee J; Chang JS; Roh MR; Jung M; Lee CK; Oh BH; Chung KY; Koom WS; Shin SJ
Cancer Res Treat; 2020 Jul; 52(3):730-738. PubMed ID: 32054150
[TBL] [Abstract][Full Text] [Related]
25. Etiologies and Outcomes of Acute Respiratory Failure in Solid Organ Transplant Recipients: Insight Into the EFRAIM Multicenter Cohort.
Messika J; Darmon M; Mal H; Pickkers P; Soares M; Canet E; Rello J; Bauer PR; van de Louw A; Lemiale V; Taccone FS; Loeches IM; Schellongowski P; Mehta S; Antonelli M; Kouatchet A; Barratt-Due A; Valkonen M; Bruneel F; Pène F; Metaxa V; Moreau AS; Burghi G; Montini L; Barbier F; Nielsen LB; Mokart D; Chevret S; Zafrani L; Azoulay E;
Transplant Proc; 2020 Dec; 52(10):2980-2987. PubMed ID: 32499142
[TBL] [Abstract][Full Text] [Related]
26. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
[TBL] [Abstract][Full Text] [Related]
27. Incidence and outcomes of invasive fungal infection among solid organ transplant recipients: A population-based cohort study.
Hosseini-Moghaddam SM; Ouédraogo A; Naylor KL; Bota SE; Husain S; Nash DM; Paterson JM
Transpl Infect Dis; 2020 Apr; 22(2):e13250. PubMed ID: 31981389
[TBL] [Abstract][Full Text] [Related]
28. Association of HLA Antigen Mismatch With Risk of Developing Skin Cancer After Solid-Organ Transplant.
Gao Y; Twigg AR; Hirose R; Roll GR; Nowacki AS; Maytin EV; Vidimos AT; Rajalingam R; Arron ST
JAMA Dermatol; 2019 Mar; 155(3):307-314. PubMed ID: 30673077
[TBL] [Abstract][Full Text] [Related]
29. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
30. Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity.
Zheng M
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36889809
[TBL] [Abstract][Full Text] [Related]
31. Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance system.
Cui X; Yan C; Xu Y; Li D; Guo M; Sun L; Zhu Z
Cancer Med; 2023 Mar; 12(5):5181-5194. PubMed ID: 36504294
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of efficacy and safety between domestic immune checkpoint inhibitors and pembrolizumab in the treatment of driver gene-negative advanced non-small cell lung cancer].
Chen YQ; Zhang YD; Yan H; Qin HY; Huang Z; Zhang X; Xiang SQ; Hu XQ; Wu F; Zhang YC; Zeng L; Yang N
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(4):282-289. PubMed ID: 38246773
[No Abstract] [Full Text] [Related]
33. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
34. Fecal Microbiota Transplant in Pediatric Solid Organ Transplant Recipients.
Rodig NM; Weatherly M; Kaplan AL; Ballal SA; Elisofon SA; Daly KP; Kahn SA
Transplantation; 2023 Sep; 107(9):2073-2077. PubMed ID: 37211643
[TBL] [Abstract][Full Text] [Related]
35. A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients.
Linares L; Cofan F; Diekmann F; Herrera S; Marcos MA; Castel MA; Farrero M; Colmenero J; Ruiz P; Crespo G; Llopis J; Garcia-Vidal C; Soriano À; Moreno A; Bodro M;
PLoS One; 2021; 16(3):e0247251. PubMed ID: 33657157
[TBL] [Abstract][Full Text] [Related]
36. Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade.
Chorti E; Kowall B; Hassel JC; Schilling B; Sachse M; Gutzmer R; Loquai C; Kähler KC; Hüsing A; Gilde C; Thielmann CM; Zaremba-Montenari A; Placke JM; Gratsias E; Martaki A; Roesch A; Ugurel S; Schadendorf D; Livingstone E; Stang A; Zimmer L
Eur J Cancer; 2024 Mar; 200():113536. PubMed ID: 38306840
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review.
Fisher J; Zeitouni N; Fan W; Samie FH
J Am Acad Dermatol; 2020 Jun; 82(6):1490-1500. PubMed ID: 31302190
[TBL] [Abstract][Full Text] [Related]
38. Clostridioides difficile infection and recurrence among 2622 solid organ transplant recipients.
Schluger A; Rosenblatt R; Knotts R; Verna EC; Pereira MR
Transpl Infect Dis; 2019 Dec; 21(6):e13184. PubMed ID: 31571380
[TBL] [Abstract][Full Text] [Related]
39.
Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
[TBL] [Abstract][Full Text] [Related]
40. Evaluating the impact of gastrointestinal episodes on the health-related quality of life of solid organ transplant recipients: sensitivity to change of the SIGIT-QoL questionnaire: Mypaciente-2 study.
Ortega F; Puig JM; Paúl-Ramos FJ; Salcedo M; Bravo JA; De la Cruz J; Lauzurica R; Miras M; Rodríguez-Goyanes G; Guinea G
Transplant Proc; 2014 Dec; 46(10):3629-36. PubMed ID: 25498101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
